{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:05:45Z","timestamp":1771437945655,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In terms of global incidence and mortality, breast cancer continues to surpass all other cancers affecting women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To explore the role of miR-596, qRT-PCR was applied to measure its expression in tissue and cell samples from 137 enrolled subjects. The regulatory interaction between miR-596 and\n                      <jats:italic>EIF5AL1<\/jats:italic>\n                      was verified by dual-luciferase reporter assays. CCK-8 and Transwell assays were utilized to respectively measure the proliferation, migration, and invasion capabilities of the two breast cancer cell lines, MCF-7 and MDA-MB-231.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A significant downregulation of miR-596 was observed in breast cancer tissues and cell lines (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Clinically, reduced miR-596 expression was associated with advanced TNM stage, lymph node metastasis, and inferior overall survival (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                      <jats:italic>EIF5AL1<\/jats:italic>\n                      was validated as a direct target gene of miR-596, and their expression levels were inversely correlated in clinical samples (\n                      <jats:italic>r<\/jats:italic>\n                      = -0.801,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Reintroduction of miR-596 markedly suppressed the proliferation, migration, and invasion of cancer cells, effects that were largely reversed by overexpressing\n                      <jats:italic>EIF5AL1<\/jats:italic>\n                      (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In breast cancer, miR-596 suppresses malignancy and predicts prognosis by targeting\n                      <jats:italic>EIF5AL1<\/jats:italic>\n                      . Thus, therapeutic modulation of this axis offers novel avenues for treatment and risk assessment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-026-00641-6","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:15:44Z","timestamp":1769051744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["miR-596 as a novel prognostic biomarker and tumor suppressor in breast cancer through targeting EIF5AL1"],"prefix":"10.1186","volume":"163","author":[{"given":"Rui","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoyong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"641_CR1","doi-asserted-by":"publisher","first-page":"144205","DOI":"10.1016\/j.electacta.2024.144205","volume":"487","author":"A Raucci","year":"2024","unstructured":"Raucci A, Cimmino W, Grosso SP, Normanno N, Giordano A, Cinti S. Based screen-printed electrode to detect miRNA-652 associated to triple-negative breast cancer. Electrochim Acta. 2024;487:144205.","journal-title":"Electrochim Acta"},{"issue":"3","key":"641_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"3","key":"641_CR3","doi-asserted-by":"publisher","first-page":"e36905","DOI":"10.1097\/MD.0000000000036905","volume":"103","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024;103(3):e36905.","journal-title":"Medicine"},{"issue":"22","key":"641_CR4","doi-asserted-by":"publisher","first-page":"11455","DOI":"10.3390\/app122211455","volume":"12","author":"MO Adebiyi","year":"2022","unstructured":"Adebiyi MO, Arowolo MO, Mshelia MD, Olugbara OO. A linear discriminant analysis and classification model for breast cancer diagnosis. Appl Sci. 2022;12(22):11455.","journal-title":"Appl Sci"},{"issue":"5","key":"641_CR5","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1002\/jcp.27486","volume":"234","author":"K Saliminejad","year":"2019","unstructured":"Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of micrornas: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451\u201365.","journal-title":"J Cell Physiol"},{"issue":"13","key":"641_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.febslet.2010.08.009","volume":"585","author":"SA Melo","year":"2011","unstructured":"Melo SA, Esteller M. Dysregulation of MicroRNAs in cancer: playing with fire. FEBS Lett. 2011;585(13):2087\u201399.","journal-title":"FEBS Lett"},{"key":"641_CR7","doi-asserted-by":"crossref","unstructured":"Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences. 2006;103(24):9136-41.","DOI":"10.1073\/pnas.0508889103"},{"key":"641_CR8","doi-asserted-by":"crossref","unstructured":"Ameya K, PP ASU, Sekar D. The impact of microRNA-596 on oral cancer: insights into tumor biology and treatment strategies. Acta Marisiensis-Seria Med. 2025;71(1).","DOI":"10.2478\/amma-2025-0007"},{"issue":"8","key":"641_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41419-022-05062-7","volume":"13","author":"C Li","year":"2022","unstructured":"Li C, Zheng H, Xiong J, Huang Y, Li H, Jin H, et al. miR-596-3p suppresses brain metastasis of non-small cell lung cancer by modulating YAP1 and IL-8. Cell Death Dis. 2022;13(8):699.","journal-title":"Cell Death Dis"},{"issue":"53","key":"641_CR10","first-page":"43","volume":"14","author":"F Zeinali Sehrig","year":"2023","unstructured":"Zeinali Sehrig F, Zaefizadeh M, Ahmadizadeh C, Alivand R, Ghorbian S. Investigating the expression of miR-509-3-5p and miR-596 in tumor tissue and tumor peripheral tissue in breast cancer patients. New Cell Mol Biotechnol J. 2023;14(53):43\u201358.","journal-title":"New Cell Mol Biotechnol J"},{"issue":"1","key":"641_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12967-020-02502-w","volume":"18","author":"X Yang","year":"2020","unstructured":"Yang X, Amgad M, Cooper LA, Du Y, Fu H, Ivanov AA. High expression of MKK3 is associated with worse clinical outcomes in African American breast cancer patients. J Translational Med. 2020;18(1):334.","journal-title":"J Translational Med"},{"issue":"10","key":"641_CR12","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1016\/j.celrep.2019.10.129","volume":"29","author":"H Manjunath","year":"2019","unstructured":"Manjunath H, Zhang H, Rehfeld F, Han J, Chang T-C, Mendell JT. Suppression of ribosomal pausing by eIF5A is necessary to maintain the fidelity of start codon selection. Cell Rep. 2019;29(10):3134\u201346. e6.","journal-title":"Cell Rep"},{"issue":"6797","key":"641_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"1","key":"641_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ijms22010027","volume":"22","author":"I Plantamura","year":"2020","unstructured":"Plantamura I, Cataldo A, Cosentino G, Iorio MV. miR-205 in breast cancer: state of the Art. Int J Mol Sci. 2020;22(1):27.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"641_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/ncrna5040053","volume":"5","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Humphries B, Yang C, Wang Z. MiR-205 dysregulations in breast cancer: the complexity and opportunities. Non-coding RNA. 2019;5(4):53.","journal-title":"Non-coding RNA"},{"issue":"23","key":"641_CR16","doi-asserted-by":"publisher","first-page":"17869","DOI":"10.1074\/jbc.M110.101055","volume":"285","author":"W Kong","year":"2010","unstructured":"Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010;285(23):17869\u201379.","journal-title":"J Biol Chem"},{"issue":"1","key":"641_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s13277-012-0570-5","volume":"34","author":"W Chen","year":"2013","unstructured":"Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of Circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumor Biology. 2013;34(1):455\u201362.","journal-title":"Tumor Biology"},{"issue":"20","key":"641_CR18","doi-asserted-by":"publisher","first-page":"9650","DOI":"10.18632\/oncotarget.2520","volume":"5","author":"C Eichelser","year":"2014","unstructured":"Eichelser C, St\u00fcckrath I, M\u00fcller V, Milde-Langosch K, Wikman H, Pantel K, et al. Increased serum levels of Circulating Exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 2014;5(20):9650.","journal-title":"Oncotarget"},{"issue":"10","key":"641_CR19","doi-asserted-by":"publisher","first-page":"e13735","DOI":"10.1371\/journal.pone.0013735","volume":"5","author":"H Zhao","year":"2010","unstructured":"Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of Circulating MiRNAs as potential biomarkers of early stage breast cancer. PLoS ONE. 2010;5(10):e13735.","journal-title":"PLoS ONE"},{"issue":"4","key":"641_CR20","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s11010-024-05136-4","volume":"480","author":"SH Mohamed","year":"2025","unstructured":"Mohamed SH, Kamal MM, Reda AM, Mesbah NM, Abo-Elmatty DM, Abdel-Hamed AR. MicroRNA-205-5p inhibits the growth and migration of breast cancer through targeting Wnt\/\u03b2-catenin co-receptor LRP6 and interacting with LncRNAs. Mol Cell Biochem. 2025;480(4):2117\u201329.","journal-title":"Mol Cell Biochem"},{"issue":"9","key":"641_CR21","doi-asserted-by":"publisher","first-page":"8361","DOI":"10.3390\/ijms24098361","volume":"24","author":"AS Anisimova","year":"2023","unstructured":"Anisimova AS, Kolyupanova NM, Makarova NE, Egorov AA, Kulakovskiy IV, Dmitriev SE. Human tissues exhibit diverse composition of translation machinery. Int J Mol Sci. 2023;24(9):8361.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"641_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215\u201333.","journal-title":"Cell"},{"issue":"1","key":"641_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/1471-2164-10-218","volume":"10","author":"Y-P Wang","year":"2009","unstructured":"Wang Y-P, Li K-B. Correlation of expression profiles between MicroRNAs and mRNA targets using NCI-60 data. BMC Genomics. 2009;10(1):218.","journal-title":"BMC Genomics"},{"issue":"1","key":"641_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12935-020-01226-7","volume":"20","author":"G-Q Wu","year":"2020","unstructured":"Wu G-Q, Xu Y-M, Lau AT. Recent insights into eukaryotic translation initiation factors 5A1 and 5A2 and their roles in human health and disease. Cancer Cell Int. 2020;20(1):142.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"641_CR25","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.3390\/ijms24076067","volume":"24","author":"Y-Y Wu","year":"2023","unstructured":"Wu Y-Y, Wu G-Q, Cai N-L, Xu Y-M, Lau AT. Comparison of human eukaryotic translation initiation factors 5A1 and 5AL1: identification of amino acid residues important for EIF5A1 lysine 50 hypusination and its protein stability. Int J Mol Sci. 2023;24(7):6067.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"641_CR26","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/cancers12041009","volume":"12","author":"V Gambardella","year":"2020","unstructured":"Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Rosell\u00f3 S, et al. Personalized medicine: recent progress in cancer therapy. Cancers. 2020;12(4):1009.","journal-title":"Cancers"},{"issue":"5","key":"641_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"key":"641_CR28","doi-asserted-by":"crossref","unstructured":"Yang L, Dang W, Kong F, Zhang X, Zheng L, Jia L et al. miR-145-5p inhibits HER2-Positive breast cancer cells via targeting ARF6. Int J Gen Med. 2025:1181\u201392.","DOI":"10.2147\/IJGM.S510358"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00641-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00641-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00641-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:07:37Z","timestamp":1771434457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-026-00641-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00641-6","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by The Ethics Committee of The People\u2019s Hospital of Shuangqiao Economic-Technological Development Zone. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and later versions. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}